Acitretin
Spezifikationen
55079-83-9CAS-Nummer
259-474-4EG-Nummer
(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acidIUPAC-Name
C21H26O3Chemische Formel
326.4 g/molMolekulargewicht
Acitretin; 55079-83-9; Etretin; Soriatane; Neotigason; Acitretine; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; Acitretina; Ro 10-1670; Ro 10-1670/000; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; DTXSID6022553; Ro-10-1670; all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; Ro-10-1670/000; LCH760E9T7; CHEBI:50173; Ro-101670000; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)-; DTXCID902553; CHEBI:50172; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-, (all-E)-; RefChem:57003; D05BB02; Trimethylmethoxyphenyl-retinoic acid; Ro101670; Ro137652; Ro 101670; Ro 137652; 259-474-4; all-trans-Acitretin; Retinoid etretin; Acitretinum; 54757-46-9; 9-cis Acitretin; MFCD00866632; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid; NCGC00163127-02; Acitretine [French]; Acitretinum [Latin]; Acitretina [Spanish]; 419534-31-9; (2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; Acetretin; Soriatane CK; Soriatane (TN); CCRIS 5534; HSDB 7187; Isoacitretin;Ro 13-7652; EINECS 259-474-4; UNII-LCH760E9T7; Neotigason;; Etretin;; U0279; Acitretin CRS; all-trans-Etretin; Acitretin [USAN:USP:INN:BAN]; 13-is Acitretin; Acitretin; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; Acitretin (Standard); Acitretin [M+H]+; Acitretin (USP/INN); ACITRETIN [INN]; ACITRETIN [MI]; ACITRETIN [HSDB]; ACITRETIN [USAN]; Spectrum5_002065; ACITRETIN [VANDF]; ACITRETIN [MART.]; ACITRETIN [USP-RS]; ACITRETIN [WHO-DD]; SCHEMBL3759; CHEMBL1131; MLS001076667; BIDD:GT0617; Acitretin - Bio-X trade mark; GTPL7598; orb1308957; ACITRETIN [ORANGE BOOK]; ACITRETIN [EP MONOGRAPH]; ACITRETIN [USP IMPURITY]; SCHEMBL29496318; HY-B0107R; ACITRETIN [USP MONOGRAPH]; GLXC-07207; HMS2234L17; HMS3259J12; HMS3714E17; HMS5079H15; 55079-83-9 (non-labelled); Acitretin, >=98.0% (HPLC); HY-B0107; MSK40189; Tox21_112012; BDBM50088429; EBC-11169; STL565770; AKOS015889991; AC-4702; CCG-220668; CS-1855; DB00459; FA11039; KS-5246; NC00723; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-; NCGC00163127-01; NCGC00163127-03; NCGC00163127-10; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; AS-12644; BA164136; SMR000499573; SY102132; CAS-55079-83-9; DB-222690; A3097; CS-0368934; NS00002571; SW199134-2; T1330; Ro-10-1670-000; C75579; D02754; EN300-117242; AB00698376-08; AB00698376_09; Acitretin 100 microg/mL in Acetonitrile:Acetone; EN300-1273239; F799738; Q341500; SR-01000763200; SR-01000763200-3; BRD-K62012036-001-13-6; BRD-K62012036-001-14-4; BRD-K90699611-001-01-4; Acitretin, British Pharmacopoeia (BP) Reference Standard; Z2312273468; Acitretin, European Pharmacopoeia (EP) Reference Standard; Acitretin, United States Pharmacopeia (USP) Reference Standard; Acitretin, Pharmaceutical Secondary Standard; Certified Reference Material; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethy l-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoicacid; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2E,4E,6E,8E)-Synonyme
